ProPhase Labs

ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. It operates through the Diagnostic Services and Consumer Products segment. The Diagnostic Services segment includes COVID-19 and other diagnostic testing services. The Consumer Products segment consists of the manufacturing, retail customers, and personal genomics products and services. The company was founded by Guy J. Quigley and Charles A. Phillips in July 1989 and is headquartered in Garden City, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ProPhase Labs achieves record revenues, Nebula Genomics poised for growth

ProPhase Labs delivered strong financial performance in 2022, showcasing a successful transformation and diversification strategy.
The company's subsidiaries, particularly Nebula Genomics and BE-Smart, offer significant growth potential and differentiation in their respective markets.
While challenges like declining COVID testing trends and financial impacts exist, strategic opportunities and efficient management position ProPhase Labs for continued success.

ProPhase Labs prioritizes value-building over earnings, eyes global growth

ProPhase Labs is strategically focusing on long-term value creation through its diverse business segments.
While facing challenges in COVID testing and profitability, the company is optimistic about revenue growth from key assets.
Opportunities in precision medicine, cancer compounds, and global expansion present avenues for future growth.

ProPhase Labs shifts focus to genetic testing, eyes global expansion

ProPhase Labs is strategically pivoting towards genetic testing with Nebula Genomics, focusing on advanced laboratory capabilities and potential revenue generation. Despite revenue declines in Q2, the company remains optimistic about future growth prospects and is actively exploring financing options for expansion.

ProPhase Labs anticipates substantial growth with innovative healthcare solutions

ProPhase Labs is strategically positioned for growth with strong demand for its subsidiaries and innovative healthcare solutions in development.
While facing challenges in market conditions and revenue guidance, the company's focus on expansion and efficiency drives optimism for future performance.
Opportunities lie in revenue and profitability increases, potential IPOs, and advancements in esophageal cancer testing techniques and therapeutics.
Investors are encouraged to consider the long-term potential of ProPhase Labs as it navigates challenges and capitalizes on growth prospects.

ProPhase Labs excels in Q4, eyes revenue growth and strategic partnerships

ProPhase Labs showcased strong historical performance, profitable business segments, and strategic growth initiatives. The company is poised for substantial revenue growth through key contracts, innovative product offerings, and expansion into new markets. Challenges in short-term profitability and regulatory restrictions are being addressed while focusing on long-term value creation and growth potential.

ProPhase Labs (PRPH) reports strong performance and explores strategic opportunities

ProPhase Labs (PRPH) showcased strong historical performance, highlighted key initiatives like Pharmaloz and Nebula Genomics, and emphasized the potential for liquidity events. Challenges include revenue growth uncertainty and transparency concerns over share count increase.

ProPhase Labs strategizes for growth amidst seasonality and liquidity concerns

ProPhase Labs is navigating mixed performance with a focus on strategic initiatives, liquidity management, and maximizing shareholder value.
The company's strengths lie in its leadership team, growth potential in precision medicine, and plans for mitigating seasonality in revenue streams.
Challenges include seasonality impact, liquidity concerns, and the need for successful execution of strategic alternatives for Pharmaloz.
Opportunities exist in partnerships for Pharmaloz, growth potential in precision medicine, and anticipated revenue growth in the upcoming quarters.

ProPhase Labs excels in Q3 with innovative healthcare solutions

ProPhase Labs' Q3 earnings call highlighted strong performance, innovative healthcare solutions, and strategic growth initiatives.
The company's focus on fiscal conservatism, cost reduction, and potential partnerships positions it for future success and market expansion.
Challenges in cost management and market dynamics are balanced by opportunities in partnerships, product expansion, and revenue growth strategies.
Overall, ProPhase Labs remains optimistic about its future prospects, emphasizing prudent financial management and growth through strategic collaborations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of ProPhase Labs Inc (NASDAQ: PRPH), a consumer healthcare and diagnostics company, jumped 32% in the extended session on Tuesday. What Happened: ProPhase said on Tuesday it has acquired mobile app company VaccTrack, which confirms a user has been vaccinated against COVID-19, for an undisclosed amount.

Why ProPhase Labs Shares Jumped 32% Today

New Reporting App Simplifies Documentation of User Vaccination and Covid Testing Statue – Easily Enables Clear Access to Air/Rail/Bus Travel, Concert & Sporting Events

ProPhase Labs Acquires Digital Covid Vaccination and Testing “Passport” Solution

GARDEN CITY, NY, March 15, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, will hold a conference call on Wednesday, March 31, 2021 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2020. A press release detailing these results will be issued prior to the call.

ProPhase Labs to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Wednesday, March 31, 2021 at 4:30 p.m. Eastern Time

PRPH has pivoted to CLIA compliant testing for COVID-19.

With Pivot To COVID-19 Testing, ProPhase Labs Could Greatly Reward Shareholders

ProPhase Labs, Inc (NASDAQ:PRPH) is one of three emerging companies that will present at Proactive's virtual investor conference on Tuesday, February 16. Hosted by Proactive's Christine Corrado, the event kicks off on Tuesday at 1 PM ET.

ProPhase Labs: Meet the team that's looking to revolutionize coronavirus testing

Company Integrates Spectrum Solutions™ SDNA-1000 Saliva Collection System for Advanced, Simultaneous Multi-Viral Detection of Infections and Viral Mutations

ProPhase Labs Begins Advanced, Saliva-based Viral PCR Multiplex-Testing for COVID-19, Influenza A & B, and Other Viruses After FDA Confirmation of Two Emergency Use Authorizations

Company to Host Business Update Shareholder's Conference Call on February 10, 2021 at 11:00 a.m. Eastern Time

ProPhase Labs Exceeding Initial Goals as Covid-19 Lab Testing Business Ramps up

- Total Company Processing Capacity On Track to Reach 60,000 Tests Per Day –

ProPhase Labs Announces Opening of Large CLIA Lab Covid Testing Facility in Garden City, New York

Garden City, NY, Jan. 21, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, today announced the closing of its previously announced public offering of 3,000,000 shares of its common stock at a public offering price of $12.50 per share, for gross proceeds of $37,500,000, before deducting underwriting discounts and commissions and offering expenses. In addition, ProPhase Labs, Inc. has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock to cover over-allotments, if any, at the public offering price, less underwriting discounts and commissions.

ProPhase Labs, Inc. Announces Closing of Public Offering

GARDEN CITY, NY, Jan. 15, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, announced today that it has commenced a proposed underwritten public offering of its common stock.

ProPhase Labs Announces Proposed Public Offering of Common Stock

Company Exceeding Near Term Goals & Expands 2021 Testing Capacity

ProPhase Labs to Present at the NobleCon17 Annual Small & Microcap Investor Conference on Tuesday, January 19, 2021 at 12:45 p.m. Eastern Time

GARDEN CITY, NY, Jan. 05, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, today announced that it has entered into a definitive securities purchase agreement with certain institutional and accredited investors to purchase, in a registered direct offering, 550,000 shares of ProPhase common stock, at a purchase price of $10.00 per share, together with warrants to purchase 275,000 shares of ProPhase common stock at a purchase price of $11.00 per share. Subject to customary closing conditions, the transaction is expected to close on Thursday, January 7, 2021.

ProPhase Labs Announces $5.5 Million Registered Direct Offering of Common Stock and Warrants

Company Expands to Meet Anticipated Demand for Increased Molecular Testing From New Business Opportunities – Aiming For Capacity to Process 50,000 Tests per Day

ProPhase Labs Expands COVID-19 Testing Capacity with New 25,000 Square Feet Testing Facility in Garden City, New York

DOYLESTOWN, Pennsylvania, Nov. 16, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, today announced net sales of $3.8 million for the three months ended September 30, 2020, compared to net sales of $2.8 million for the three months ended September 30, 2019. The Company incurred a net loss from continued operations for the three months ended September 30, 2020 of $569,000, or ($0.05) per share, compared to a net loss from continued operations of $428,000, or ($0.04) per share, for the three months ended September 30, 2019. For the three months ended September 30, 2020, the Company also recognized income from discontinued operations of $161,000, or $0.01 per share. The Company incurred a net loss for the three months ended September 30, 2020 of $408,000, or ($0.04) per share, compared to a net loss of $428,000, or ($0.04) per share, for the three months ended September 30, 2019.

ProPhase Labs Reports Financial Results for the Three and Nine Months Ended September 30, 2020

DOYLESTOWN, PA , Nov. 10, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase Labs”), a diversified medical science and technology company, today announced that management will present at the Virtual Fall Investor Summit taking place November 16th – 18th, 2020.

ProPhase Labs to Present at the Virtual Fall Investor Summit on Monday, November 16, 2020 at 2:30 p.m. Eastern Time

DOYLESTOWN, Pennsylvania, Nov. 02, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, announced today that it has completed the acquisition of Confucius Plaza Medical Laboratory Corp. (“Confucius Labs”), a Clinical Laboratory Improvement Amendments (CLIA) accredited laboratory headquartered in Old Bridge, New Jersey.

ProPhase Labs Completes Acquisition of CLIA Accredited Lab and Provides Corporate Update

DOYLESTOWN, Pennsylvania, Oct. 23, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, announced today a definitive agreement to acquire a Clinical Laboratory Improvement Amendments (CLIA) accredited laboratory. The lab is approved for a variety of important medical tests, including COVID-19 and Respiratory Pathogen Panel (RPP) Molecular tests. The lab will be owned by the Company's new subsidiary, ProPhase Diagnostics, Inc., which has been formed to aggregate medical testing business opportunities and expand the lab's capabilities and capacity.

ProPhase Labs Announces Definitive Agreement to Acquire CLIA Accredited Lab Certified for COVID-19 and Upper Respiratory Testing

Company Enters into Consulting Agreement and Amended and Restated Promissory Note and Security Agreement with Predictive Laboratories, Inc. to Further These Plans

ProPhase Labs Engages Industry Expert to Advise on Possible Acquisition of CLIA Accredited Labs Certified for COVID-19 and Other Testing

DOYLESTOWN, Pennsylvania, Sept. 30, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, has engaged international investor relations specialists MZ Group (MZ) to lead a comprehensive strategic investor relations and financial communications program across all key markets.

ProPhase Labs Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program

DOYLESTOWN, Pennsylvania, Sept.  23, 2020  (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH,  www.ProPhaseLabs.com ) today announced that it has entered into an at-the-market (“ATM”) equity offering sales agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”), under which the Company may, from time to time, offer and sell shares of its common stock through AGP, as sales agent.

ProPhase Labs Announces At-The-Market Equity Facility

DOYLESTOWN, Pennsylvania, Sept.  18, 2020  (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com) today announced that it has closed on a $10 million unsecured debt financing. The Company has issued two unsecured, partially convertible, promissory notes for an aggregate principal amount of $10 million (the “Notes”).

ProPhase Labs Announces $10 Million Unsecured Debt Financing

DOYLESTOWN, Pennsylvania, Aug.  11, 2020  (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com) today announced net sales of $3.6 million for the three months ended June 30, 2020, compared to net sales of $1.7 million for the three months ended June 30, 2019. The Company recognized net income for the three months ended June 30, 2020 of $70,000, or $0.01 per share, compared to a net loss of $1.2 million, or ($0.11) per share, for the three months ended June 30, 2019.

ProPhase Labs Reports Financial Results for the Three and Six Months Ended June 30, 2020

DOYLESTOWN, Pennsylvania, May  12, 2020  (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH,  www.ProPhaseLabs.com ) today announced net sales of $1.9 million for the three months ended March 31, 2020, compared to net sales of $2.3 million for the three months ended March 31, 2019.

ProPhase Labs Reports Financial Results for the Three Months Ended March 31, 2020

DOYLESTOWN, Pennsylvania, March  25, 2020  (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com) today announced its net sales were $9.9 million for the year ended December 31, 2019, as compared to net sales of $13.1 million for the year ended December 31, 2018.

ProPhase Labs Reports Financial Results  for the Year Ended December 31, 2019

DOYLESTOWN, PA, Nov.  20, 2019  (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com), a vertically integrated manufacturer, marketer and distributor of a diversified range of over-the-counter dietary supplements (“ProPhase” or “Company”), announced today that its Board of Directors has declared a special cash dividend in the amount of $0.25 per share on its common stock, payable on December 12, 2019 to stockholders of record as of December 3, 2019.

News for ProPhase Labs Stock (PRPH)